drugset
drugset / Trial / NCT05195112

Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat

NCT05195112 ↗

Phase 3 Completed 240 enrolled Medy-Tox
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the Efficacy and Safety of MT921 in Subjects with Moderate to Severe Submental fat compared with Placebo.

Timeline

Start
2021-12-24
Primary completion
2023-02-18
Completion
2023-02-18

Drugs

EvaluationDrugModalityDoseRoute
Subject MT921 Unknown 3 unknown Other

Indications

No indication recorded.